JANX014 / Janux Therapeutics - LARVOL DELTA

Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - P1 | N=43 | Recruiting | Sponsor: Janux Therapeutics

First-in-human • New P1 trial • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

Janux Therapeutics…announced that the first patient has been dosed in a Phase 1 clinical trial of JANX014 in patients with metastatic castration-resistant prostate cancer (mCRPC) (Businesswire) - "The Phase 1 study is a first-in-human, open-label, multicenter study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of JANX014 in adults with mCRPC."

First-in-human • Trial status • Castration-Resistant Prostate Cancer